Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of γ-secretase activity

Journal of Alzheimer's Disease

Volumn 43, Issue 3, 2015, Pages 797-807

  Song, Hyundong ^a   Chang, Yu Jin ^a   Moon, Minho ^a   Park, Sarah Kyua ^b   Tran, Phuong Thao ^a   Hoang, Van Hai ^a   Lee, Jeewoo ^a   Mook Jung, Inhee ^a  

^a Seoul National University   (South Korea)

^b Case School   (United States)

Author keywords

5XFAD; Alzheimer's disease; glutaminyl cyclase; pyroglutamate amyloid ; secretase

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; BETA SECRETASE; ENZYME; ENZYME INHIBITOR; GAMMA SECRETASE; GLUTAMINYL CYCLASE; GLUTAMINYL CYCLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NICASTRIN; PEN2 PROTEIN; PRESENILIN; PROTEIN; PYROGLUTAMATE A BETA; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG; AMINOACYLTRANSFERASE; GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE; SECRETASE;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN; CATALYSIS; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEMORY; MEMORY DISORDER; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SENILE PLAQUE; SUBICULUM; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOLOGY; PLAQUE, AMYLOID; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMINOACYLTRANSFERASES; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; MICE; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID;

EID: 84914689049     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141356     Document Type: Review

References (39)

1. Terry RD, Katzman R (1983) Senile dementia of the Alzheimer type. Ann Neurol 14, 497-506.
2. Dillen K, Annaert W (2006) A two decade contribution of molecular cell biology to the centennial of Alzheimer's disease: Are we progressing toward therapy? Int Rev Cytol 254, 215-300.
3. Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 120, 545-555.
4. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
5. Hook V, Schechter I, Demuth HU, Hook G (2008) Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biol Chem 389, 993-1006.
6. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG (2000) Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 276, 422-427.
7. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S (1996) Amino-and carboxyl-terminal heterogeneity of betaamyloid peptides deposited in human brain. Neurosci Lett 215, 173-176.
8. Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ (1996) Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloidbeta 42(43) deposit in diffuse plaques. Am J Pathol 149, 1823-1830.
9. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D'Arrigo C, Bachi A, Cattaneo A, Canale C, Torrassa S, Saido TC, Markesbery W, Gam betti P, Tabaton M (2005) beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 280, 34186-34192.
10. Russo C, Salis S, Dolcini V, Venezia V, Song XH, Teller JK, Schettini G (2001) Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. Neurobiol Dis 8, 173-180.
11. Mori H, Takio K, Ogawara M, Selkoe DJ (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 267, 17082-17086.
12. Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, Willbold D, Funke SA, Schilling S, Demuth HU (2009) Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 48, 7072-7078.
13. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, Schettini G (2002) Pyroglutamate-modified amyloid beta-peptides-AbetaN3(pE)-strongly affect cultured neuron and astrocyte survival. J Neurochem 82, 1480-1489.
14. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 14, 457-466.
15. Moon M, Hong HS, Nam DW, Baik SH, Song H, Kook SY, Kim YS, Lee J, Mook-Jung I (2012) Intracellular amyloid-beta accumulation in calcium-binding proteindeficient neurons leads to amyloid-beta plaque formation in animal model of Alzheimer's disease. J Alzheimers Dis 29, 615-628.
16. Shirotani K, Tsubuki S, Lee HJ, Maruyama K, Saido TC (2002) Generation of amyloid beta peptide with pyroglutamate at position 3 in primary cortical neurons. Neurosci Lett 327, 25-28.
17. Schilling S, Niestroj AJ, Rahfeld JU, Hoffmann T, Wermann M, Zunkel K, Wasternack C, Demuth HU (2003) Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators. J Biol Chem 278, 49773-49779.
18. Hartlage-Rubsamen M, Staffa K, Waniek A, Wermann M, Hoffmann T, Cynis H, Schilling S, Demuth HU, Rossner S (2009)Developmental expression and subcellular localization of glutaminyl cyclase in mouse brain. Int J Dev Neurosci 27, 825-835.
19. Stephan A, Wermann M, von Bohlen A, Koch B, Cynis H, Demuth HU, Schilling S (2009) Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics. FEBS J 276, 6522-6536.
20. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU (2004) Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett 563, 191-196.
21. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med 14, 1106-1111.
22. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140.
23. Buchholz M, Hamann A, Aust S, Brandt W, Bohme L, Hoffmann T, Schilling S, Demuth HU, Heiser U (2009) Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement. J Med Chem 52, 7069-7080.
24. Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW, Mook-Jung I (2006) ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J 20, 157-159.
25. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C (2001) Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch.EMBO Rep 2, 835-841.
26. Boo JH, Song H, Kim JE, Kang DE, Mook-Jung I (2009) Accumulation of phosphorylated beta-catenin enhancesROSinduced cell death in presenilin-deficient cells. PLoS One 4, e4172.
27. Jiang L, He L, Fountoulakis M (2004) Comparison of protein precipitation methods for sample preparation prior to proteomic analysis. J Chromatogr A 1023, 317-320.
28. Song H, Boo JH, Kim KH, Kim C, Kim YE, Ahn JH, Jeon GS, Ryu H, Kang DE, Mook-Jung I (2013) Critical role of presenilin-dependent gamma-secretase activity in DNA damage-induced promyelocytic leukemia protein expression and apoptosis. Cell Death Differ 20, 639-648.
29. Cynis H, Schilling S, Bodnar M, Hoffmann T, Heiser U, Saido TC, DemuthHU(2006) Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim Biophys Acta 1764, 1618-1625.
30. Schilling S, Hoffmann T,Wermann M, Heiser U,Wasternack C, Demuth HU (2002) Continuous spectrometric assays for glutaminyl cyclase activity. Anal Biochem 303, 49-56.
31. Maeda J, Zhang MR, Okauchi T, Ji B, Ono M, Hattori S, Kumata K, Iwata N, Saido TC, Trojanowski JQ, Lee VM, Staufenbiel M, Tomiyama T, Mori H, Fukumura T, Suhara T, Higuchi M (2011) In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci 31, 4720-4730.
32. Adams JP, Sweatt JD (2002) Molecular psychology: Roles for the ERK MAP kinase cascade in memory. Annu Rev Pharmacol Toxicol 42, 135-163.
33. Shaywitz AJ, Greenberg ME (1999) CREB: A stimulusinduced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68, 821-861.
34. Cynis H, Scheel E, Saido TC, Schilling S, Demuth HU (2008) Amyloidogenic processing of amyloid precursor protein: Evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry 47, 7405-7413.
35. Jawhar S, Wirths O, Schilling S, Graubner S, Demuth HU, Bayer TA (2011) Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Abeta formation, induces behavioral deficits, and glutaminyl cyclase knockout rescues the behavioral phenotype in 5XFAD mice. J Biol Chem 286, 4454-4460.
36. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA (2009) Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 118, 487-496.
37. Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L (2004) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165, 1289-1300.
38. Christensen DZ, Bayer TA, Wirths O (2010) Intracellular Ass triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging 31, 1153-1163.
39. Christensen DZ, Kraus SL, Flohr A, Cotel MC, Wirths O, Bayer TA (2008) Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol 116, 647-655.